TC BioPharm Limited Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Name:	TCBP_IfrsStatementLineItems
Namespace Prefix:	TCBP_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Share capital and premium.

No definition available.

Name:	TCBP_ShareCapitalAndPremium
Namespace Prefix:	TCBP_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The nominal value of capital issued.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 78
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard
-URIDate 2022-03-24

Name:	ifrs-full_IssuedCapital
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2022-03-24
-Paragraph 79
-Subparagraph a
-Clause iv
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iv&doctype=Standard
-URIDate 2022-03-24

Name:	ifrs-full_NumberOfSharesOutstanding
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

The amount received or receivable from the issuance of the entity's shares in excess of nominal value.